Dr Harsh Vardhan launches CSIR partnered clinical trials website on repurposed Covid drugs

Published On 2020-10-21 04:00 GMT   |   Update On 2022-12-17 05:37 GMT
Advertisement

New Delhi: Dr Harsh Vardhan, Minister of Science & Technology, Health and Family Welfare and Earth Sciences, today launched a website that gives comprehensive information about the numerous COVID-19 clinical trials that CSIR is engaged in partnership with Industry, other government departments and ministries.

Called CuRED or CSIR Ushered Repurposed Drugs, the website provides information about the drugs, diagnostics and devices including the current stage of the trials, partnering institutions and their role in the trials and other details. The site can be accessed at https://www.iiim.res.in/cured/http://db.iiim.res.in/ct/index.php.

Advertisement

Also Read: Dr Harsh Vardhan Launches Second Phase Of Thalassemia Bal Sewa Yojna

The Minister lauded the efforts of CSIR for being at the forefront of the ongoing fight against COVID-19 and prioritizing clinical trials, generating data for their regulatory approval and helping launch drugs and diagnostics in the market. He commended the approach of using repurposed drugs and also, synthesizing COVID-19 drugs through new processes and transferring to Industry.

CSIR is exploring multiple combination clinical trials of anti-virals with host-directed therapies for the potential treatment of COVID-19. CSIR is also working with the Ministry of AYUSH for clinical trials of AYUSH drugs and has undertaken safety & efficacy trials of AYUSH prophylactics and therapeutics based on individual plant-based compounds and in combination. Five clinical trials involving Withaniasomnifera, Tinosporacordifolia + Piper longum(in combination), Glycyrrhizaglabra, Tinosporacordifolia & Adhatodavasica (individually and in combination) and AYUSH-64 formulation are undergoing safety and efficacy trials.

A key clinical trial of CSIR is the Sepsivac (Mw) against COVID -19 in partnership with Cadila. The phase 2 clinical trial has been completed successfully on critically ill COVID-19 patients, and more extensive Phase 3 trial is on the anvil. Further, the Phase 2 trial of phytopharmaceutical AQCH on Covid-19 patients with Sun Pharma and DBT is underway.

In addition to clinical trials of repurposed drugs and vaccines, CSIR has been involved in clinical trials of diagnostics and devices.

Dr Harsh Vardhan emphasized that while the scientists are working on developing drugs and vaccines, as of now, social distancing, wearing masks and other precautions are essential and must be duly followed if we have to win the fight against COVID-19.

Dr. Shekhar C Mande, Secretary, DSIR and DG-CSIR, Dr.Ranjana Aggarwal, Dir, NISTADS and Dr. Geetha Vani Rayasam, Senior Principal Scientist & Head, Science Communication and Dissemination Directorate CSIR HQ, were present on the occasion. CSIR Directors, Heads of Departments, and Scientists involved in Clinical Trials joined the event virtually.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News